Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of CRD-4730 in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)

NCT07750873 is registered in ClinicalTrials.gov with Cardurion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07750873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07750873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of CRD-4730 in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
July 15, 2026
Completion date
September 30, 2028
Enrollment
525 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with reduced ejection fraction (hfref)